Detalhe da pesquisa
1.
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
J Thromb Thrombolysis
; 57(1): 39-49, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37566295
2.
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database.
Diabetes Obes Metab
; 25(2): 602-610, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054168
3.
Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry.
BMC Med
; 20(1): 326, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36056426
4.
Correction: Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
J Thromb Thrombolysis
; 57(1): 178, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37814089
5.
Response to letter from Du et al. regarding article 'Sodium-glucose cotransporter-2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?'
Diabetes Obes Metab
; 25(2): 630-633, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36333970
6.
Impact of ABC (Atrial Fibrillation Better Care) pathway adherence in high-risk subgroups with atrial fibrillation: A report from the ESC-EHRA EORP-AF long-term general registry.
Eur J Intern Med
; 107: 60-65, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36372692